Uniqure Announces Alignment With FDA On Accelerated Approval Pathway For AMT-130 In Huntington’S Disease

T-Reuters
10 Dec 2024

Uniqure :Uniqure Announces Alignment With Fda On Key Elements Of Accelerated Approval Pathway For Amt-130 In Huntington’S Disease.Uniqure Nv - Fda Agrees Cuhdrs May Serve As Intermediate Clinical Endpoint.Uniqure Nv - Fda Agrees Phase I/Ii Data May Serve As Basis For Bla.Uniqure Nv - Fda Agrees No Additional Pre-Submission Study Needed For Amt-130.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10